Rubius Therapeutics, Inc. (RUBY) financial statements (2021 and earlier)

Company profile

Business Address 399 BINNEY STREET, SUITE 300
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments176283404
Cash and cash equivalents9192307
Short-term investments8519197
Restricted cash and investments0 1
Other undisclosed current assets5610
Total current assets:182289414
Noncurrent Assets
Operating lease, right-of-use asset4047
Property, plant and equipment545763
Restricted cash and investments222
Other noncurrent assets000
Total noncurrent assets:9610665
TOTAL ASSETS:278395479
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15138
Accounts payable578
Accrued liabilities10 
Employee-related liabilities85 
Interest and dividends payable00 
Debt 11 
Other undisclosed current liabilities131012
Total current liabilities:283420
Noncurrent Liabilities
Long-term debt and lease obligation1088666
Long-term debt, excluding current maturities755024
Capital lease obligations41
Operating lease, liability3337
Liabilities, other than long-term debt100
Deferred rent credit  0
Other liabilities10 
Other undisclosed noncurrent liabilities  0
Total noncurrent liabilities:1088766
Total liabilities:13612186
Stockholders' equity
Stockholders' equity attributable to parent142274393
Common stock000
Additional paid in capital622587543
Accumulated other comprehensive income (loss)00(0)
Accumulated deficit(480)(313)(150)
Total stockholders' equity:142274393
TOTAL LIABILITIES AND EQUITY:278395479

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:11 
Operating expenses(166)(170)(92)
Other undisclosed operating loss(1)(1) 
Operating loss:(166)(170)(92)
Nonoperating income (expense)(1)62
Investment income, nonoperating280
Other nonoperating income11 
Interest and debt expense(4)(3)(0)
Loss before gain (loss) on sale of properties:(172)(166)(90)
Other undisclosed net income430
Net loss available to common stockholders, diluted:(168)(163)(89)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(168)(163)(89)
Comprehensive loss:(168)(163)(89)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(168)(163)(89)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: